➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Express Scripts
Baxter

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 10,093,732

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,093,732
Title:Antagonists of IL-6 to prevent or treat thrombosis
Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
Inventor(s): Smith; Jeffrey T. L. (Bellevue, WA)
Assignee: ALDERBIO HOLDINGS LLC (Las Vegas, NV)
Application Number:14/933,141
Patent Claims:see list of patent claims

Details for Patent 10,093,732

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial ALDERBIO HOLDINGS LLC (Las Vegas, NV) 2028-11-25 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial ALDERBIO HOLDINGS LLC (Las Vegas, NV) 2028-11-25 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial ALDERBIO HOLDINGS LLC (Las Vegas, NV) 2028-11-25 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial ALDERBIO HOLDINGS LLC (Las Vegas, NV) 2028-11-25 RX Orphan search
Novartis ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial ALDERBIO HOLDINGS LLC (Las Vegas, NV) 2028-11-25 RX search
Novartis KESIMPTA ofatumumab SOLUTION;SUBCUTANEOUS 125326 002 2009-10-26   Start Trial ALDERBIO HOLDINGS LLC (Las Vegas, NV) 2028-11-25 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Start Trial ALDERBIO HOLDINGS LLC (Las Vegas, NV) 2028-11-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Harvard Business School
Express Scripts
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.